Advanced Liver Care & Metabolic Hepatology

Dr. Chetan Kalal

Hepatologist | Transplant Physician | Fatty Liver & Fibrosis Specialist

Evidence-based care for:

• Fatty liver disease (MASLD/MASH)

• Liver fibrosis & FibroScan assessment

• Cirrhosis management

• Metabolic liver disease

• Obesity-related liver disorders

• Liver transplant hepatology

👉 Focused on early fibrosis detection, metabolic risk, and long-term liver outcomes.

🔥

“Treating liver disease beyond ultrasound—focused on fibrosis, metabolism, and outcomes.”

🏥 About Dr. Chetan Kalal

Dr. Chetan Kalal is a leading hepatologist and transplant physician with expertise in managing complex liver diseases including fatty liver disease (MASLD/MASH), liver fibrosis, cirrhosis, and metabolic liver disorders.

His clinical approach combines:

• Advanced hepatology

• Obesity and metabolic medicine

• Fibrosis-focused risk assessment

• Evidence-based individualized care

Dr. Kalal has received national and international academic recognition and is actively involved in advancing practical hepatology for Indian patients.

🔍

• Hepatologist in India

• Liver specialist India

• Fatty liver specialist

• MASH treatment

• MASLD management

• FibroScan specialist

• Liver fibrosis doctor

• Obesity and liver disease

• Cirrhosis treatment

• Metabolic hepatology

• Semaglutide fatty liver

• Liver transplant physician

📈

Fatty Liver Disease (MASLD/MASH)

Fatty liver disease is increasingly linked to obesity, diabetes, insulin resistance, and visceral adiposity—particularly in Indian patients who develop metabolic disease at lower BMI.

Key Clinical Focus:

• Fibrosis risk assessment

• Early disease detection

• Weight-loss strategies

• Metabolic optimization

• Long-term liver protection

Fibrosis Matters More Than Fat

In fatty liver disease, fibrosis—not fat—is the strongest predictor of:

• Cirrhosis

• Liver failure

• Portal hypertension

• Liver cancer risk

• Mortality

Every patient with fatty liver should undergo fibrosis risk assessment.

Tools include:

• FIB-4

• FibroScan

• Elastography

• Advanced fibrosis pathways

Obesity & Metabolic Liver Disease

Modern hepatology is increasingly metabolic hepatology.

Indian patients commonly present with:

• Visceral obesity

• Hypertriglyceridemia

• Prediabetes / diabetes

• Sarcopenic obesity

• Fatty liver at lower BMI

Treatment strategies may include:

• Lifestyle intervention

• GLP-1–based therapy

• Saroglitazar

• Bariatric/metabolic referral

📚

Frequently Asked Questions

What is the difference between fatty liver and fibrosis?

Fatty liver refers to fat accumulation in the liver, whereas fibrosis refers to liver scarring. Fibrosis is more important because it predicts long-term complications and prognosis.

Can fatty liver be reversed?

Yes. Early-stage fatty liver disease can often improve with sustained weight loss, metabolic control, and appropriate medical management.

When should FibroScan be done?

FibroScan is useful in patients with:

• Fatty liver

• Diabetes

• Obesity

• Elevated liver enzymes

• Metabolic syndrome

• Suspected fibrosis risk

Do all fatty liver patients need medication?

No. Treatment depends on fibrosis risk, obesity severity, diabetes status, triglycerides, and metabolic profile.

🚀

“Fibrosis matters more than fat.”

“Treat phenotype, not just ultrasound.”

“Modern hepatology is metabolic hepatology.”

🎯

Dr. Chetan Kalal

Specialist in:

• Metabolic hepatology

• Fatty liver disease

• Fibrosis-focused liver care

• Obesity-related liver disease

• Advanced hepatology & transplant medicine